Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG-T187
- Development stage
- Phase 1
- Lead developer
- BeOne Medicines
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
BG-T187 is a trispecific antibody developed by BeiGene for the treatment of advanced solid tumors, including lung cancer and gastrointestinal neoplasms. It targets both the epidermal growth factor receptor (EGFR) and c-Met (hepatocyte growth factor receptor), functioning as an EGFR antagonist and c-Met inhibitor. The drug is designed to block EGFR signaling, inhibit c-Met activity, stimulate T lymphocytes, and induce antibody-dependent cell cytotoxicity. As of early 2025, BG-T187 is in Phase 1 clinical trials as both monotherapy and in combination with other agents for patients with advanced or metastatic solid tumors[1][2][3][4][5][6][8].
- Other names
- anti-EGFR×c-MET×c-MET trispecific antibodyEGFR x MET x MET trispecific antibody
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on BG-T187.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG-T187.